Şunu aradınız:: hypercalcemia (İngilizce - Maltaca)

hypercalcemia
iperkalċimja

hypercalcemia common
iperkalċimja komuni

marked hypercalcemia may be evidence of hidden hyperparathyroidism.
iperkalċemja notevoli tista ’ tkun xhieda ta ’ iperparatajrojdiżmu mistur.

hypercalcemia greater than 2.76 mmol/ l, hyperuricemia rare:
livell għoli ta ’ kalċju fid- demm iżjed minn 2. 76 mmol/ l, livell għoli ta ’ aċidu uriku fid- demm rari:

hypercalcemia greater than 3.25 mmol/ l vascular disorders common:
livell għoli ta ’ kalċju fid- demm iżjed minn 3. 25 mmol/ l disturbi vaskulari komuni:

hypercalcemia was transient and was reported most frequently in the first 3 months of treatment.
l-iperkalċimja kienet għaddiena u ġiet irrapportata bl-aktar mod frekwenti fl-ewwel 3 xhur tal-kura.

the hypercalcemia was transient and was reported most frequently in the first 3 months of treatment.
l- iperkalċimja kienet għaddiena u ġiet irrapportata l- aktar ta ’ sikwit fl- ewwel 3 xhur tal- kura.

however, sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity.
madankollu, rapporti ta ’ każijiet sporadiċi ssuġġerew li l- iperkalċemija tista ’ tippridisponi ‘ l- pazjenti għat- tossiċita ’ b’ digitalis.

the effects of overdose that might be expected include delayed hypercalcemia, nausea, vomiting, dizziness and headache.
l-effetti ta’ doża eċċessiva li wieħed jista’ jistenna jinkludu iperkalċimja ttardjata, dardir, rimettar, sturdament u wġigħ ta’ ras.

frequency of administration for treatment of tumour induced hypercalcemia, bondronat concentrate for solution for infusion is generally given as a single infusion.
frekwenza ta ’ l- amministrazzjoni għal trattament ta’ iperkalċemja kkawżat minn tumur, bondronat konċentrat għal soluzzjoni għall - infużjoni jingħata ġeneralment bħala infużjoni waħda.

hypercalcemia was reported in 25.3% of patients and hypercalciuria in 39.3% of patients treated with preotact.
l-iperkalċimja kienet irrapportata f’25.3% tal-pazjenti u l-iperkalċurja f’39.3% tal-pazjenti kkurati bi preotact.

hypercalcemia and/or hypercalciuria reflect the known pharmacodynamic actions of parathyroid hormone in the gastrointestinal tract, the kidney, and the bone.
l- iperkalċimja kienet irrapportata

hypercalcemia, postulated to contribute to an increased incidence of adrenal medullary tumours in risperdal consta-treated rats, was observed in both dose groups.
iperkalċimja, li wieħed jassumi li tikkontribwixxi għal inċidenza ogħla ta ’ tumuri tal- medulla adrenali f’ firien ikkurati b’ risperdal consta, kienet osservata fiż- żewġ gruppi ta ’ doża.

caution should be exercised in patients receiving cardiac glucosides due to the risk of digitalis toxicity if hypercalcemia develops (see section 4.5).
trid tingħata attenzjoni għal dawk il-pazjenti li jkunu qegħdin jirċievu glukosidi kardijaċi minħabba r-riskju ta’ tossiċità minn digitalis kemm-il darba tiżviluppa iperkalċemija (ara sezzjoni 4.5).

patients with pre-existing hypercalcemia and/or hypercalciuria preotact has been studied in patients with pre-existing hypercalcemia and/or hypercalciuria.
pazjenti b’ iperkalċimja u/ jew iperkalċurja diġà preżenti

from the knowledge of the mechanism of action, combined use of preotact and cardiac glucosides may predispose patients to digitalis toxicity if hypercalcemia develops (see section 4.4).
minn dak li huwa magħruf dwar il-mod ta’ kif jaħdem, l-użu flimkien ta’ preotact u glukosidi kardijaċi jista’ jippredisponi lill-pazjenti għal tossiċità mid-diġitalis jekk tiżviluppa l-iperkalċimja (ara sezzjoni 4.4).

with pre-existing hypercalcemia and other disturbances in the phosphocalcic metabolism with metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and paget’s disease of the bone)
b’mard metaboliku ta’ l-għadam differenti minn osteoporożi primarja (fosthom iperparatirojdiżmu u l-marda ta’ l-għadam ta’ paget)

based on two placebo-controlled studies involving 2642 postmenopausal osteoporotic women, hypercalcemia was reported in 25.3% of patients treated with preotact compared to 4.3% of placebo- treated patients.
ibbażat fuq żewġ studji kliniċi kkontrollati bil-plaċebo li kienu jinvolvu 2642 mara b’osteoporożi ta’ wara l-menopawsa, l-iperkalċimja ġiet irrapportata f’25.3% tal-pazjenti kkurati bi preotact meta mqabbel ma’ 4.3% tal-pazjenti kkurati bi plaċebo.